Investments in private pharmaceutical and biotech companies slumped by 24% in April, with the market being once again dominated by US companies, a Scrip analysis has found.
Investments in private pharmaceutical and biotech companies slumped by 24% in April, with the market being once again dominated by US companies, a Scrip analysis has found.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.
A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.
Complete datasets on Tezspire and depemokimab caught the eye at the AAAAI/WAO meeting in San Diego and while the AstraZeneca/Amgen drug appears to be more efficacious, the GSK candidate offers greater convenience.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
